Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3452095

Cc1nc(-c2cnn(C(CC3CC3)C3CCCC3)c2)c2ccn(CC[Si](C)(C)C)c2n1.O=C(O)C(F)(F)F

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 12/20 0.33
JAK1 P23458 11/20 0.33
JAK3 P52333 9/20 0.33
TYK2 P29597 7/20 0.33
ABL1 P00519 3/20 0.33
GSK3B P49841 2/20 0.33
AURKB Q96GD4 2/20 0.33
KDR P35968 1/20 0.33
STAT3 P40763 1/20 0.33
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
DAPK3 O43293 2/20 0.31
PAK4 O96013 2/20 0.31
RET P07949 2/20 0.31
LTK P29376 2/20 0.31
CSNK1A1 P48729 2/20 0.31
CLK2 P49760 2/20 0.31
TNK2 Q07912 2/20 0.31
ROCK1 Q13464 2/20 0.31
DYRK1A Q13627 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL101065 0.88 JAK1 (0.32) JAK2JAK1JAK3TYK2ABL1
Trifluoroacetic Acid SCHEMBL29540586 0.88 JAK1 (0.32) JAK2JAK1JAK3TYK2ABL1
Trifluoroacetic Acid SCHEMBL3452093 0.84 JAK1 (0.39) JAK2JAK1JAK3TYK2ABL1
Trifluoroacetic Acid SCHEMBL101064 0.80 JAK1 (0.38) JAK2JAK1JAK3TYK2ABL1
Trifluoroacetic Acid SCHEMBL100922 0.73 JAK2 (0.42) JAK2JAK1JAK3TYK2ABL1
Trifluoroacetic Acid SCHEMBL27929273 0.73 JAK2 (0.48) JAK2JAK1JAK3TYK2ABL1
Trifluoroacetic Acid SCHEMBL101063 0.70 JAK2 (0.64) JAK2JAK1JAK3TYK2ABL1
SCHEMBL99547 0.70 JAK2 (0.33) JAK2JAK1JAK3TYK2ABL1
SCHEMBL15412937 0.68 JAK2 (0.38) JAK2JAK1JAK3TYK2ABL1
SCHEMBL15413003 0.68 JAK2 (0.33) JAK2JAK1JAK3TYK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541425-B2 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE CORPORATION (US) 2013-09-24 US disclosed
US-20100022522-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS Incyte Corporationn, a Delaware corporation 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022522-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 JAK2 3/4885JAK1 2/4885JAK3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.